Concepedia

Mark Fereshteh

MF

19

Publications

2.1K

Citations

17

H-Index

2001

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Biocon (India)

Duke Medical Center

Duke University Hospital

Bristol-Myers Squibb (India)

Mark Fereshteh is an author at Bristol-Myers Squibb (United States) specializing in medicine, tumor biology, and cell signaling.

Top concepts

Publications per year

2001–2022

19

Publications

19

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

Chen Zhao, Alan Chen, Catriona Jamieson et al. · Nature · 2009 · 852 citations · Full text

, , +10

Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth

James Kim, Jean Y. Tang, Ruoyu Gong et al. · Cancer Cell · 2010 · 506 citations · Full text

, , +6

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Alexander Muik, Elena Garralda, Friederike Gieseke et al. · Cancer Discovery · 2022 · 104 citations · Full text

The Nuclear Receptor Coactivator Amplified in Breast Cancer-1 Is Required for <i>Neu</i> (ErbB2/HER2) Activation, Signaling, and Mammary Tumorigenesis in Mice

Mark Fereshteh, Maddalena T. Tilli, Sung Eun Kim et al. · Cancer Research · 2008 · 96 citations · Full text

Epidermal Growth Factor Receptor Tyrosine Phosphorylation and Signaling Controlled by a Nuclear Receptor Coactivator, Amplified in Breast Cancer 1

Tyler Lahusen, Mark Fereshteh, Annabell S. Oh et al. · Cancer Research · 2007 · 72 citations · Full text

Rows per page

1–5 of 19